Submitted:
12 November 2023
Posted:
13 November 2023
You are already at the latest version
Abstract
Keywords:
Introduction
Material and Methods of Research
Results
Discussion
Conclusion
Ethical Statement
Funding
Competing Interests
Ethical approval
Conflicts of Interest
References
- Bentzen, S.M. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006, 6, 702–713. [Google Scholar] [CrossRef] [PubMed]
- Birgisson, H.; Påhlman, L.; Gunnarsson, U.; Glimelius, B. Late adverse effects of radiation therapy for rectal cancer – a systematic overview. Acta Oncol. 2007, 46, 504–516. [Google Scholar] [CrossRef] [PubMed]
- Bertholet, J.; Knopf, A.; Eiben, B.; McClelland, J.; Grimwood, A.; Harris, E.; Menten, M.; Poulsen, P.; Nguyen, D.T.; Keall, P.; Oelfke, U. Real-time intrafraction motion monitoring in external beam radiotherapy. Phys Med Biol. 2019, 64, 15TR01. [Google Scholar] [CrossRef] [PubMed]
- Fiorino, C.; Valdagni, R.; Rancati, T.; Sanguineti, G. Dose–volume effects for normal tissues in external radiotherapy: Pelvis. Radiother Oncol. 2009, 93, 153–167. [Google Scholar] [CrossRef] [PubMed]
- Andreyev, H.J.N. Gastrointestinal Problems after Pelvic Radiotherapy: the Past, the Present and the Future. Clin Oncol. 2007, 19, 790–799. [Google Scholar] [CrossRef] [PubMed]
- Lu, L.; Li, W.; Chen, L.; Su, Q.; Wang, Y.; Guo, Z.; Lu, Y.; Liu, B.; Qin, S. Radiation-induced intestinal damage: latest molecular and clinical developments. Future Oncol. 2019, 15, 4105–4118. [Google Scholar] [CrossRef] [PubMed]
- McBride, W.H.; Schaue, D. Radiation-induced tissue damage and response. J Pathol. 2020, 250, 647–655. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, M.; Ahmed, R. Radiation in Gastroenterology. Gastroenterol Res. 2022, 15, 285–296. [Google Scholar] [CrossRef] [PubMed]
- Prieto, S.P.; Reed, C.L.; James, H.M.; Quinn, K.P.; Muldoon, T.J. Differences in colonic crypt morphology of spontaneous and colitis-associated murine models via second harmonic generation imaging to quantify colon cancer development. BMC Cancer. 2019, 19, 428. [Google Scholar] [CrossRef] [PubMed]
- Brentnall, M.; Rodriguez-Menocal, L.; De Guevara, R.L.; Cepero, E.; Boise, L.H. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 2013, 14, 32. [Google Scholar] [CrossRef] [PubMed]
- Gu, Q.; Jiao, S.; Duan, K.; Wang, Y.X.; Petralia, R.S.; Li, Z. The BAD-BAX-Caspase-3 Cascade Modulates Synaptic Vesicle Pools via Autophagy. J Neurosci Off J Soc Neurosci. 2021, 41, 1174–1190. [Google Scholar] [CrossRef] [PubMed]
- Kanth, P.; Rajan, T. Chromogranin A and Ki67 Marker in Normal Colon, Serrated Polyp and Colorectal Tubular Adenoma: 1470. Off J Am Coll Gastroenterol ACG 2011, 106, S562. [Google Scholar] [CrossRef]
- Akedo, I.; Ishikawa, H.; Ioka, T.; Kaji, I.; Narahara, H.; Ishiguro, S.; Suzuki, T.; Otani, T. Evaluation of epithelial cell proliferation rate in normal-appearing colonic mucosa as a high-risk marker for colorectal cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2001, 10, 925–930. [Google Scholar]
- Andrés-Sánchez, N.; Fisher, D.; Krasinska, L. Physiological functions and roles in cancer of the proliferation marker Ki-67. J Cell Sci. 2022, 135, jcs258932. [Google Scholar] [CrossRef] [PubMed]
- Zhou, M.; Liu, X.; Li, Z.; Huang, Q.; Li, F.; Li, C.Y. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. Int J Cancer. 2018, 143, 921–930. [Google Scholar] [CrossRef] [PubMed]
- Olsson, M.; Zhivotovsky, B. Caspases and cancer. Cell Death Differ. 2011, 18, 1441–1449. [Google Scholar] [CrossRef] [PubMed]
- Kikuchi, Y.; Dinjens, W.N.; Bosman, F.T. Proliferation and apoptosis in proliferative lesions of the colon and rectum. Virchows Arch. 1997, 431, 111–117. [Google Scholar] [CrossRef] [PubMed]
Authors

| Control | 2 Gy | 25 Gy | |
| Degenerative changes | 0.00 ± 00 | 0.31 ± 0.10 | 2.37 ± 0.43 |
| Dystrophic changes in the epithelium | 0.00 ± 00 | 0.24 ± 0.06 | 1.30 ± 0.45 |
| Number of Goblet cells | 0.00 ± 0.13 | 0.43 ± 0.21 | 1.64 ± 0.37 |
| Number of muscle cells | 0.00 ± 0.23 | 0.36 ± 0.35 | 1.58 ± 0.49 |
| Number of macrophages | 0.00 ± 0.21 | 0.41 ± 0.24 | 1.69± 0.29 |
| Full-bloodedness | 0.00 ± 00 | 0.27 ± 0.43 | 2.32 ± 0.51 |
| Group | n | organ length, mm | wall thickness, µm | outer diameter, mm | inner diameter, µm |
| Control | 10 | 10,7 ± 1,4 | 66,8 ± 25,9 | 3,1 ± 0,7 | 79,7 ± 20,4 |
| 2 Gy | 20 | 10,1 ± 1,8 | 64,8 ± 24,6 | 3,0 ± 0,8 | 72,7 ± 20,9 |
| 25 Gy | 30 | 9,3 ± 2,1 | 60,3 ± 22,6 | 2,8 ± 1,1 | 51,9 ± 21,7 |
| Marker | Control (I) | 2 Gy (II) | 25 Gy (III) |
| caspasa-3 | 14.5±3.9% | 17.11±4.79a | 28.7±8.2%b |
| Ki-67 | 19.45±5.12% | 16.34±3.56a | 11.14±6.23%b |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).